
Certara, Inc. — Investor Relations & Filings
Certara, Inc. is a company that accelerates drug discovery and development through the use of proprietary biosimulation software, technology, and expert services. It provides an end-to-end platform that supports clients across the entire drug development lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's solutions leverage predictive simulation, data-driven modeling, and advanced analytics to help pharmaceutical and biotechnology organizations optimize trial design, justify dosing decisions, and navigate regulatory requirements. Key software products include Simcyp, Phoenix, and Pinnacle 21. Certara's offerings are designed to de-risk development, enhance efficiency, and increase the likelihood of bringing new medicines to patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | |
| ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | |
| 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | |
| 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | |
| 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 35223149 | 8-K - Certara, Inc. (0001827090) (Filer) | 2026-04-22 | English | ||
| 33256151 | ARS - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 33255090 | DEF 14A - Certara, Inc. (0001827090) (Filer) | 2026-04-03 | English | ||
| 32899219 | 4 - CERTARA, INC. (0001827090) (Filer) | 2026-03-02 | English | ||
| 32899221 | 10-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 32899220 | 8-K - CERTARA, INC. (0001827090) (Filer) | 2026-02-26 | English | ||
| 13319431 | Director's Dealing 2026 | 2026-01-12 | English | ||
|
2025
8 filings
| |||||
| 13319432 | FORM 8-K | 2025-12-11 | English | ||
| 13319433 | Major Shareholding Notification 2025 | 2025-11-25 | English | ||
| 13319434 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
| 13319435 | Director's Dealing 2025 | 2025-11-12 | English | ||
| 13319436 | 10-Q | 2025-11-06 | English | ||
| 13319437 | 8-K | 2025-11-06 | English | ||
| 13319438 | FORM 8-K | 2025-10-16 | English | ||
| 13319439 | Major Shareholding Notification 2025 | 2025-10-09 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
NOVOGENE CO., LTD.
Global provider of genomic services, NGS solutions, and bio…
|
688315 | CN | Professional, scientific and te… |
|
Novoheart Holdings Inc.
Engineering bioartificial human heart surrogates for drug d…
|
NVH | CA | Professional, scientific and te… |
|
NOVOPROTEIN SCIENTIFIC INC.
Develops recombinant proteins and enzymes for life sciences…
|
688137 | CN | Professional, scientific and te… |
|
NOXOPHARM LIMITED
Clinical-stage developer of novel treatments for cancer and…
|
NOX | AU | Professional, scientific and te… |
|
NUFORMIX PLC
Pharmaceutical developer using cocrystal technology to repu…
|
NFX | GB | Professional, scientific and te… |
|
Nurix Therapeutics, Inc.
Clinical-stage biopharma developing protein degradation the…
|
NRIX | US | Professional, scientific and te… |
|
NYRADA INC.
Develops small molecule therapeutics for cardiovascular hea…
|
NYR | AU | Professional, scientific and te… |
|
OLIPASS CORPORATION
An R&D company developing RNA therapeutics using its propri…
|
244460 | KR | Professional, scientific and te… |
|
OmniAb, Inc.
A technology platform for therapeutic antibody discovery us…
|
OABIW | US | Professional, scientific and te… |
|
ONCIMMUNE HOLDINGS PLC
Immunodiagnostics company specializing in antibody and auto…
|
ONC | GB | Professional, scientific and te… |
Certara, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31699/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31699 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31699 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31699 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31699}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Certara, Inc. (id: 31699)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.